About Valerie Odegard
Valerie Odegard is a director at Odyssey Therapeutics.
Form D filings also name Valerie Odegard as a director at Abata Therapeutics.
Valerie Odegard reports to the SEC as a director or officer of 2 public companies, including ARS Pharmaceuticals (SPRY).
Valerie Odegard first appears on SEC filings in 2020.
Experience
This experience comes from SEC filings. The years are when the filings name Valerie Odegard in the role, so the role may have started earlier or lasted longer.
AI
ARS Pharmaceuticals, Inc.
President and CSO
2020 – 2022 · Public company (SPRY)
Key Colleagues at Startups
The people Valerie Odegard works with at each company, as listed on that company's latest Form D.
Odyssey Therapeutics, Inc. · Form D, Dec 4, 2025
CG
Carl Gordon
Director
CN
Carolyn Ng
Director
GG
Gary Glick
President & CEO, director
TW
Timothy Walbert
Director
Paulina Hill
Director
NL
Nan Li
Director
JL
Jeffrey Leiden
Director
JH
Jason Haas
CFO
NT
Nia Tatsis
Director
KP
Ksenija Pavletic
Director
SC
Shelley Chu
Director
LS
Lan Smith
Director
JC
Jill Carroll
Director
Abata Therapeutics, Inc. · Form D, Dec 27, 2023
SS
Samantha Singer
Chief Executive Officer and director
LD
Leonard Dragone
Executive officer
SS
Stephen Sofen
Executive officer
SL
Sandy Lazzari
Executive officer
SC
Shelley Chu
Director
NM
Nagesh Mahanthappa
Director
JT
John Trzupek
Executive officer
AC
Abbie Celniker
Director
MF
Mitch Finer
Director
DK
David Kaufman
Director
LK
Lorence Kim
Director
EM
Ellen Cahir-Mcfarland
Executive officer